| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT05827614 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR… |
Trial terminated |
| 2026-06-09 | NCT05827614 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR… |
date change Primary completion moved earlier: 2026-09-30 -> 2026-03-17 |
| 2026-06-09 | NCT05827614 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR… |
date change Completion moved earlier: 2027-03-31 -> 2026-03-17 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT02411448 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated… | Metastatic Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated… | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT02193282 | Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung… | Lung Non-Squamous Non-Small Cell Carcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Lymphoma, Non-Hodgkin | Recruiting |
| NCT06997068 | Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and… | Metastatic Oral Cavity Carcinoma | Recruiting |
| NCT04981509 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage… | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Recruiting |
| NCT00076310 | OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer | Head and Neck Cancer | Active, Not Recruiting |
| NCT04172779 | Erlotinib for Hepatocellular Carcinoma Chemoprevention | Cirrhosis, Liver | Not Yet Recruiting |
| NCT01708954 | Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or… | Recurrent Lung Non-Small Cell Carcinoma | Active, Not Recruiting |
| NCT03137771 | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients… | Recurrent Non-Small Cell Lung Carcinoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06483555 | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel | Pancreatic Adenocarcinoma | Recruiting |
| NCT06545695 | Epidermal Growth Factor Receptor Inhibition for Keratinopathies | Epidermolytic Ichthyosis | Not Yet Recruiting |
| NCT07418177 | Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD | AMD - Age-Related Macular Degeneration | Not Yet Recruiting |
| Phase 1 | |||
| NCT00045201 | Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced… | Adult Solid Neoplasm | Active, Not Recruiting |
| NCT00878163 | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in… | Adult Solid Neoplasm | Active, Not Recruiting |
| NCT01660971 | Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients… | Metastatic Pancreatic Adenocarcinoma | Active, Not Recruiting |
| NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| Not specified | |||
| NCT02194738 | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That… | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Active, Not Recruiting |